Acorda Therapeutics Inc (ACOR) Stock

DelistedNasdaq: ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.

0.66
Final close · Apr 11, 2024

ACOR is no longer traded. Acorda Therapeutics was delisted from the Nasdaq in April 2024.

Prices on this page are historical; the last trade was April 11, 2024 at $0.66.

Acorda Therapeutics stock price history

Split-adjusted closes, 2006–2024

ACOR final trading statistics

Final close
$0.66
Final trading day
Apr 11, 2024
Market cap at delisting
$821.0K
Shares outstanding
1.24M
Final 52-week range
$0.45 – $18.20
Avg. volume (final 3 mo.)
130,435
All-time high (split-adj.)
$5340.00 · Jan 2015
All-time low (split-adj.)
$0.66 · Apr 2024
Return since IPO
-99.9%
Beta
1.46
Book value / share
-$127.17
Price / book
-0.01
Final 52 wk
0.4518.20

Acorda Therapeutics earnings per share

Earnings per share

Acorda Therapeutics revenue & net income

RevenueNet income

Acorda Therapeutics annual financials

Fiscal yearRevenueNet incomeEPS
FY2023$117.63M-$252.9M—
FY2022$118.57M-$65.9M-$4.84
FY2021$129.07M-$104.0M-$7.49
FY2020$152.97M-$99.6M-$9.04
FY2019$192.41M-$273.0M-$10.32

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Acorda Therapeutics stock FAQ

What happened to Acorda Therapeutics stock?

Acorda Therapeutics stock was delisted from the Nasdaq. Its final close was $0.66 on April 11, 2024.

Is ACOR stock still trading?

No. ACOR was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.

What was the last price of ACOR stock?

ACOR closed at $0.66 on its final trading day, April 11, 2024, for a market value of about $821.0K.

What were Acorda Therapeutics's revenue and earnings in its last full fiscal year?

Acorda Therapeutics reported revenue of $117.63M and net income of -$252.9M in fiscal 2023, its last full year as a public company.

When did Acorda Therapeutics go public?

Acorda Therapeutics Inc stock began trading on February 10, 2006.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →